- Home
- PCT vs PHVS Comparison
PCT vs PHVS Comparison
Compare PCT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCT
- PHVS
- Stock Information
- Founded
- PCT 2015
- PHVS 2015
- Country
- PCT United States
- PHVS Switzerland
- Employees
- PCT N/A
- PHVS N/A
- Industry
- PCT Environmental Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- PCT Utilities
- PHVS Health Care
- Exchange
- PCT Nasdaq
- PHVS Nasdaq
- Market Cap
- PCT 1.8B
- PHVS 1.6B
- IPO Year
- PCT N/A
- PHVS 2021
- Fundamental
- Price
- PCT $9.55
- PHVS $25.64
- Analyst Decision
- PCT Strong Buy
- PHVS Buy
- Analyst Count
- PCT 4
- PHVS 6
- Target Price
- PCT $15.50
- PHVS $36.50
- AVG Volume (30 Days)
- PCT 3.9M
- PHVS 213.3K
- Earning Date
- PCT 11-06-2025
- PHVS 11-12-2025
- Dividend Yield
- PCT N/A
- PHVS N/A
- EPS Growth
- PCT N/A
- PHVS N/A
- EPS
- PCT N/A
- PHVS N/A
- Revenue
- PCT $5,660,000.00
- PHVS N/A
- Revenue This Year
- PCT N/A
- PHVS N/A
- Revenue Next Year
- PCT $355.83
- PHVS N/A
- P/E Ratio
- PCT N/A
- PHVS N/A
- Revenue Growth
- PCT N/A
- PHVS N/A
- 52 Week Low
- PCT $5.40
- PHVS $11.51
- 52 Week High
- PCT $17.37
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- PCT 32.24
- PHVS 67.94
- Support Level
- PCT $9.59
- PHVS $21.02
- Resistance Level
- PCT $11.42
- PHVS $22.35
- Average True Range (ATR)
- PCT 0.71
- PHVS 1.23
- MACD
- PCT -0.22
- PHVS 0.31
- Stochastic Oscillator
- PCT 2.40
- PHVS 98.07
About PCT PureCycle Technologies Inc. Common stock
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.